Do Not Add DHEA to Compounded Testosterone Cream for Menopausal Women
Major clinical practice guidelines explicitly recommend against using compounded testosterone preparations and against the generalized use of DHEA in women due to lack of efficacy data and safety concerns 1, 2.
Guideline-Based Recommendations
Against Compounded Preparations
The 2019 Global Consensus Statement on testosterone therapy specifically states that recommendations for testosterone therapy do not apply to compounded preparations 1. The 2014 Endocrine Society guidelines go further, suggesting against treatment of women with testosterone preparations formulated by pharmacies due to lack of data concerning efficacy and safety 2.
Against DHEA Use
The Endocrine Society recommends against the generalized use of DHEA for women because the indications are inadequate, and evidence of efficacy and long-term safety are lacking 2. This is a strong recommendation (Grade 1) despite low-quality evidence.
Why This Combination Is Problematic
Lack of Standardization
Compounded preparations have several critical issues:
- No FDA oversight or quality control
- Inconsistent dosing and absorption
- Unknown pharmacokinetics
- Cannot monitor appropriately for supraphysiological levels
- Risk of patient overuse 2
DHEA's Limited Evidence Base
While DHEA may have some benefits, the evidence is insufficient for routine use:
- No proven benefit for quality of life in postmenopausal women 3
- Associated with androgenic side effects (primarily acne, OR 3.77) 3
- Effects on menopausal symptoms are inconsistent and unclear 3
- Only modest improvement in sexual function (SMD 0.31) 3
Specific Exception: Intravaginal DHEA
The only evidence-supported use of DHEA in menopause is low-dose intravaginal DHEA (not systemic or compounded with testosterone) for genitourinary syndrome of menopause, specifically moderate to severe dyspareunia 4, 5. This is an FDA-approved preparation with demonstrated efficacy and safety data.
What to Do Instead
For Sexual Dysfunction (HSDD)
If treating hypoactive sexual desire disorder:
- Use FDA-approved transdermal testosterone preparations (patches, gels) designed for women if available 2
- Target physiological testosterone concentrations for premenopausal women 1
- Monitor testosterone levels at baseline, 3-6 weeks after initiation, then every 6 months 2
- Expected benefit: approximately one additional satisfying sexual event per month 1
For Genitourinary Symptoms
If treating vulvovaginal atrophy or dyspareunia:
- First-line: Low-dose vaginal estrogen therapy 5
- Alternative: Vaginal DHEA (prasterone) - FDA-approved formulation 4, 5
- Alternative: Oral ospemifene 5
- Not systemic or compounded DHEA with testosterone
Monitoring Concerns
With compounded preparations, you cannot:
- Reliably assess for supraphysiological levels
- Ensure consistent dosing
- Separate effects of testosterone vs DHEA
- Apply evidence-based dosing guidelines
Common Pitfalls to Avoid
- Do not assume DHEA adds benefit to testosterone - no evidence supports this combination
- Do not use compounded preparations when FDA-approved options exist - they lack safety and efficacy data
- Do not prescribe DHEA for general "androgen deficiency" - this syndrome is not well-defined in women 2
- Do not skip monitoring - if testosterone is used, levels must be checked regularly to prevent excessive exposure
The Evidence Hierarchy
The strongest evidence (Level I, Grade A) supports:
- Testosterone therapy in physiological doses improves sexual function in postmenopausal women with HSDD 1
- Intravaginal DHEA improves dyspareunia 4
- Compounded preparations lack this evidence base 1, 2
The androgenic side effects of DHEA (acne, hirsutism) 3 combined with testosterone would likely be additive, increasing adverse effects without proven additional benefit.